A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.
AstraZeneca France Medical Director, MD
Study Director
AstraZeneca
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
D7913C00148
NCT00247481
September 2002
June 2005
Name | Location |
---|